Compare WMG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMG | GH |
|---|---|---|
| Founded | 1929 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 13.2B |
| IPO Year | 2020 | 2018 |
| Metric | WMG | GH |
|---|---|---|
| Price | $29.73 | $108.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 21 |
| Target Price | $36.07 | ★ $99.48 |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $6,707,000,000.00 | $902,569,000.00 |
| Revenue This Year | $5.41 | $35.00 |
| Revenue Next Year | $5.86 | $26.80 |
| P/E Ratio | $42.95 | ★ N/A |
| Revenue Growth | 4.37 | ★ 30.38 |
| 52 Week Low | $25.56 | $34.55 |
| 52 Week High | $36.64 | $113.91 |
| Indicator | WMG | GH |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 60.00 |
| Support Level | $29.75 | $97.31 |
| Resistance Level | $30.97 | $113.91 |
| Average True Range (ATR) | 0.73 | 3.84 |
| MACD | 0.08 | 0.52 |
| Stochastic Oscillator | 37.91 | 65.36 |
Warner Music is the third-largest of the three major record companies. Recorded music accounts for most of the firm's revenue, with the segment housing notable record labels including Atlantic Records, Warner Records, Elektra Records. Some of the most successful current artists signed to record deals with Warner include Ed Sheeran, Bruno Mars, Cardi B, and Dua Lipa. Warner's remaining revenue comes from its publishing business, where Warner Chappell represents more than 180,000 songwriters and composers, some of whom are also Warner recording artists but many of whom are not recording artists or are attached to other labels. Warner Chappell controls more than 1 million musical compositions. Access Industries controls 98% of Warner's voting rights, while holding a 72% economic interest.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.